HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients.

Autor: Marianne Tuefferd, Jérôme Couturier, Françoise Penault-Llorca, Anne Vincent-Salomon, Philippe Broët, Jean-Paul Guastalla, Djelila Allouache, Martin Combe, Béatrice Weber, Eric Pujade-Lauraine, Sophie Camilleri-Broët

Publikováno v: PLoS ONE, Vol 2, Iss 11, p e1138 (2007)

Despite a typically good response to first-line combination chemotherapy, the prognosis for patients with advanced ovarian cancer remains poor because of acquired chemoresistance. The use of targeted therapies such as trastuzumab may potentially impr

Externí odkaz: https://doaj.org/article/d59996534aba453f8a42346e85b2de2c

supplementary table 3 from PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients

Autor: Suzy M. Scholl, Philippe Beuzeboc, Sébastien Armanet, Corine Plancher, Benard Asselain, Alhassane Diallo, Virginie Fourchotte, AnaTereza Nadan, Audrey Margogne, Ivan Bieche, Quentin Leroy, Virginie Bernard, Karine Peignaux, Laurence Gladieff, Maud Aumont, Dominique Berton-Rigaud, Laurence Gonzague, Mathieu Minsat, Claire Brunaud, Béatrice Weber, Hervé Curé, Sophie Maillard, Emmanuel Sevin, Florence Joly, Christine Kerr, Michel Fabbro, Marius Pop, Thierry Petit, Peter Petrow, Laurence Thomas, Anne Floquet, Maud Kamal, Anne de la Rochefordiere

supplementary table 3. Response evaluation at 2 time points

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::210d5039bb658b60425ae97530e92071
https://doi.org/10.1158/1078-0432.22458287

Data from PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients

Autor: Suzy M. Scholl, Philippe Beuzeboc, Sébastien Armanet, Corine Plancher, Benard Asselain, Alhassane Diallo, Virginie Fourchotte, AnaTereza Nadan, Audrey Margogne, Ivan Bieche, Quentin Leroy, Virginie Bernard, Karine Peignaux, Laurence Gladieff, Maud Aumont, Dominique Berton-Rigaud, Laurence Gonzague, Mathieu Minsat, Claire Brunaud, Béatrice Weber, Hervé Curé, Sophie Maillard, Emmanuel Sevin, Florence Joly, Christine Kerr, Michel Fabbro, Marius Pop, Thierry Petit, Peter Petrow, Laurence Thomas, Anne Floquet, Maud Kamal, Anne de la Rochefordiere

Purpose: EGFR is frequently overexpressed in cervical cancer, suggesting EGFR blockade as a promising treatment approach. Cetuximab, an anti EGFR antibody, used conjointly with radiochemotherapy, was feasible in first-line treatment of cervix carcino

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b169a22951a7aa96706287286e6b2f99
https://doi.org/10.1158/1078-0432.c.6523898

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21)

Autor: Andrés Poveda, Anne Floquet, Jonathan A Ledermann, Rebecca Asher, Richard T Penson, Amit M Oza, Jacob Korach, Tomasz Huzarski, Sandro Pignata, Michael Friedlander, Alessandra Baldoni, Tjoung-Won Park-Simon, Kenji Tamura, Gabe S Sonke, Alla Lisyanskaya, Jae-Hoon Kim, Elias Abdo Filho, Tsveta Milenkova, Elizabeth S Lowe, Phil Rowe, Ignace Vergote, Eric Pujade-Lauraine, Tomasz Byrski, Patricia Pautier, Philipp Harter, Nicoletta Colombo, Giovanni Scambia, Maria Nicoletto, Fiona Nussey, Andrew Clamp, Richard Penson, Amit Oza, Andrés Poveda Velasco, Manuel Rodrigues, Jean-Pierre Lotz, Frédéric Selle, Isabelle Ray-Coquard, Diane Provencher, Aleix Prat Aparicio, Laura Vidal Boixader, Clare Scott, Mayu Yunokawa, Jacques Medioni, Nicolas Pécuchet, Coraline Dubot, Thibault De La Motte Rouge, Marie-Christine Kaminsky, Béatrice Weber, Alain Lortholary, Christine Parkinson, Jonathan Ledermann, Sarah Williams, Susana Banerjee, Jonathan Cosin, James Hoffman, Marie Plante, Allan Covens, Gabe Sonke, Florence Joly, Holger Hirte, Amnon Amit, Koji Matsumoto, Sergei Tjulandin, Jae Hoon Kim, Laurence Gladieff, Roberto Sabbatini, David O'Malley, Patrick Timmins, Daniel Kredentser, Nuria Laínez Milagro, Maria Pilar Barretina Ginesta, Ariadna Tibau Martorell, Alfonso Gómez De Liaño Lista, Belén Ojeda González, Linda Mileshkin, Masaki Mandai, Ingrid Boere, Petronella Ottevanger, Joo-Hyun Nam, Elias Filho, Salima Hamizi, Francesco Cognetti, David Warshal, Elizabeth Dickson-Michelson, Scott Kamelle, Nathalie McKenzie, Gustavo Rodriguez, Deborah Armstrong, Eva Chalas, Paul Celano, Kian Behbakht, Susan Davidson, Stephen Welch, Limor Helpman, Ami Fishman, Ilan Bruchim, Magdalena Sikorska, Anna Słowińska, Wojciech Rogowski, Mariusz Bidziński, Beata Śpiewankiewicz, Antonio Casado Herraez, César Mendiola Fernández, Martina Gropp-Meier, Toshiaki Saito, Kazuhiro Takehara, Takayuki Enomoto, Hidemichi Watari, Chel Hun Choi, Byoung-Gie Kim, Jae Weon Kim, Roberto Hegg

Publikováno v: Lancet Oncology, 22, 5, pp. 620-631
Lancet Oncology, 22, 620-631
The Lancet Oncology, 22(5), 620-631. Lancet Publishing Group

Contains fulltext : 241226.pdf (Publisher’s version ) (Closed access) BACKGROUND: Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has previously been shown to extend progression-free survival versus placebo when given to patients with re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::327550b0b53fe7a798b4b4246c0e4f41
https://doi.org/10.1016/s1470-2045(21)00073-5

PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients

Autor: Anne de la Rochefordière, Ivan Bièche, Virginie Fourchotte, Florence Joly, Emmanuel Sevin, Béatrice Weber, Mathieu Minsat, Benard Asselain, Anne Floquet, Maud Kamal, Suzy Scholl, Maud Aumont, Quentin Leroy, Laurence Thomas, Marius Pop, Alhassane Diallo, Sophie Maillard, Hervé Curé, Michel Fabbro, Peter Petrow, Philippe Beuzeboc, Thierry Petit, K. Peignaux, Laurence Gladieff, Corine Plancher, Laurence Gonzague, Virginie Bernard, Claire Brunaud, Christine Kerr, Dominique Berton-Rigaud, AnaTereza Nadan, Sebastien Armanet, Audrey Margogne

Publikováno v: Clinical Cancer Research. 21:2530-2537

Purpose: EGFR is frequently overexpressed in cervical cancer, suggesting EGFR blockade as a promising treatment approach. Cetuximab, an anti EGFR antibody, used conjointly with radiochemotherapy, was feasible in first-line treatment of cervix carcino

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc8441ba22352e90389a827923769dc1
https://doi.org/10.1158/1078-0432.ccr-14-2368